The Association for Promotion of Research in Precision Medicine Haifa, Israel
Founder and Director The Chil and Berta Weissmann Professor of Precision Medicine B. Rappaport Faculty of Medicine, Technion – Israel Institute of Technology Member, National Israeli Academy of Scientific Medicine
Understanding the origins of breast cancer in younger women.
The underlying cause of most breast cancers is unknown. Continuous funding from BCRF enabled Dr. Rennert and his team to develop one of the largest breast cancer studies in the world, incorporating 30,000-plus individuals—of Israeli and Arab descent—with and without breast cancer. This study now has 20 years’ worth of data that inform health habits, risk factors and trends in breast cancer incidence and mortality. Biological samples from this study, collected and analyzed over time, now benefit from new analytical technologies such as artificial intelligence, and are subjected to retroactive tests to develop new insights.
Dr. Rennert and his team have examined a diverse group of over 10,000 women in Northern Israel that includes 1600 women diagnosed before age 46. With genetic data, family and reproductive histories, and behavioral data gathered from these women, the team can compare women with and without cancer.
In the coming year, the team will study tumor genetics to explore immune pathways involved in breast cancer development and progression. They will calculate risk scores that incorporate all the factors for various sub-groups based on genetic and behavioral patterns that have emerged. The aim is for these risk scores to guide personalized preventative interventions.
Gad Rennert, MD, PhD has been chairman of the Carmel Medical Center Department of Community Medicine and Epidemiology since 1992. He is a professor and the head of the public health and epidemiology teaching group at the Technion Faculty of Medicine.
Professor Rennert is also Director of the National Israeli Cancer Control Center and the Department of Epidemiology and Disease Prevention of Clalit and is leading its National Personalized Medicine Program offering testing, advice and policy on individualized molecular testing which dictates cancer risk and suitability for cancer treatments. He is responsible for the national breast and colorectal cancer detection programs in Israel and is a member of the National Oncology Council.
In 1984, Professor Rennert received his medical degree from Ben-Gurion Medical School. He received his PhD in Public Health from the University of North Carolina. He focuses his studies on understanding the behavioral and biological causes of cancer, with special emphasis on gene-environment interactions. He has been an invited speaker in key conferences, such as the Personalized Medicine World Conference, UPCP, American Society of Clinical Oncology, American Association of Cancer Research, St. Galen Cancer Prevention conference and San Antonio Breast Cancer Symposium.
In addition to his activities at the Technion, Dr. Rennert is a reviewer for more than 30 international journals, an associate editor of two and serves on 10 editorial boards. He has published more than 200 papers in leading journals such as the NEJM, Science, and Nature.
2008
The Delta Air Lines Award
Please remember BCRF in your will planning. Learn More
Leave your mark.
Join the Evelyn H. Lauder Legacy Society with your bequest for research.
